8月13日，Liquidia Technologies盘中下跌5.12%，报83.545美元/股，成交额1.39亿美元。
消息面上，公司于8月12日盘前发布第二季度财报，Q2实现每股收益0.74美元，较去年同期亏损0.49美元大幅扭亏；营收1.717亿美元，同比增长约18.5倍，核心产品YUTREPIA净销售额约1.704亿美元，环比增长31%，独立患者处方数约5,900人。尽管营收超出市场一致预期的1.685亿美元，但EPS未达FactSet预期的0.76美元，叠加此前股价已充分反映高增长预期，市场出现获利回吐。此外，美银证券此前已将公司评级从"买入"下调至"中性"，目标价79美元，亦对市场情绪形成一定压制。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.